Knight Announces Normal Course Issuer Bid
July 11, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, July 11, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today...
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
May 09, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an...
Knight Therapeutics Reports First Quarter 2024 Results
May 09, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial...
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
May 08, 2024 18:32 ET
|
Knight Therapeutics
MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the...
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City
May 07, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, May 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia,...
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call
May 02, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024...
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 09, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia,...
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
March 28, 2024 11:03 ET
|
Knight Therapeutics
MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on...
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
March 21, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
March 14, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and...